Novel anticoagulants in atrial fibrillation: focused update

Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/8091

DC Field	Value	Language
dc.contributor.author	Poposka, Lidija	en_US
dc.date.accessioned	2020-05-11T13:32:50Z	-
dc.date.available	2020-05-11T13:32:50Z	-
dc.date.issued	2013-07-15	-
dc.identifier.uri	http://hdl.handle.net/20.500.12188/8091	-
dc.description.abstract	Novel oral anticoagulants are safer than Vitamin K antagonists (warfarin) in respect to the occurrence of bleeding, especially in terms of intracranial hemorrhage. Furthermore they are non-inferior and to a certain degree are superior in comparison to warfarin, when it comes to the prevention of ischemic stroke in patients with atrial fibrillation (AF).	en_US
dc.language.iso	en	en_US
dc.publisher	European Society of Cardiology	en_US
dc.relation.ispartof	e-Journal of Cardiology Practice	en_US
dc.subject	atrial fibrillation	en_US
dc.title	Novel anticoagulants in atrial fibrillation: focused update	en_US
dc.type	Article	en_US
dc.identifier.volume	11	-
dc.identifier.issue	26	-
item.fulltext	With Fulltext	-
item.grantfulltext	open	-
crisitem.author.dept	Faculty of Medicine	-
Appears in Collections:	Faculty of Medicine: Journal Articles